Cancer Supportive Care Drugs Market Analysis | 2022-2028

Market Highlights

The Cancer Supportive Care Drugs Market was estimated at US$ 20.9 billion in 2021 and is expected to grow at a CAGR of 2.04% during 2022-2028 to reach US$ ~21.40 billion in 2028.

Wish to get a free sample? Register Here

The development of biosimilars and the approval and use of targeted treatments, which have fewer side effects than conventional chemotherapy drugs, are anticipated to restrain the market growth. The aging population, increased cancer incidence, and widespread use of chemotherapy in low- and middle-income areas are all driving forces in the market. Cancer treatment has been significantly impacted by the global COVID-19 pandemic. The American Society of Clinical Oncology reports that throughout the pandemic, there was a marked decrease in visits, cancer tests, surgeries, and therapy.

Additionally, there was a considerable decline in the number of hospital outpatient evaluation and management (E&M) visits (74%), new patient E&M visits (70%), and current patient E&M visits (60%) overall. However, the general state of affairs began to normalize in the majority of regions around the second quarter of 2021. The increasing geriatric population and rising cancer prevalence are two of the key reasons propelling market expansion. In the next twenty years, there will likely be 28.4 million new instances of cancer, up 47% from 2020, according to Globocan. In addition, older people are more vulnerable to cancer; in developing nations, the average lifespan now exceeds 80 years.

For the treatment of individuals with triple-negative breast cancer, it is indicated. It is an antibody-drug combination that, unlike chemotherapy and other conventional treatments, only targets and kills certain infected cells through its poisonous chemical molecule. The popularity of biosimilars and generic medications is another issue impeding market expansion. Branded drug sales are being hampered by the introduction of biosimilar versions of popular medications.

Numerous research reports have been released on the use of NSAIDs (non-steroidal anti-inflammatory drugs) in the treatment of cancer. For instance, a research study titled "Non-Steroidal Anti-Inflammatory Drugs in Colorectal Cancer Chemoprevention" published in February 2021 noted that there is mounting evidence from epidemiologic, preclinical, and clinical studies that non-steroidal anti-inflammatory drugs (NSAIDs) have a positive impact on colorectal cancer chemoprevention. The main method by which they lower the risk of colorectal polyps is by inhibiting cyclooxygenase-2. Additionally, using COX-2 along with non-COX-2 medications during the follow-up could reduce the risk of second cancer, as could taking more than one NSAID, according to a research study published in November 2021, titled "Nonsteroidal Anti-Inflammatory Drugs Reduce Second Cancer Risk in Patients with Breast Cancer: A Nationwide Population-Based Propensity Score-Matched Cohort Study in Taiwan."

Several investments/guidelines in the industry have been directed in recent years, which would boost the overall market:

Around two-thirds of all new cancer cases are diagnosed in persons 65 years of age and older, according to the SEER Database of the U.S. National Cancer Institute, demonstrating that aging can make people more susceptible to such diseases. Major firms are mainly concentrating on the development of novel targeted medicines for the treatment of cancer as a result of the surge in technical breakthroughs. It has fewer side effects than conventional therapies like chemotherapy. These elements may limit market expansion during the anticipated term.

Segments Analysis

By Drug Class Type

The market has been segmented into G-CSFs (Granulocyte-colony Stimulating Factors), ESAs (Erythropoiesis Stimulating Agents), anti-emetics, bisphosphonates, opioids, NSAIDs, and others. The Granulocyte Colony Stimulating Factor (G-CSF) category had the highest revenue. It is the main option for treating neutropenia brought on by cancer. It is one of the most frequently prescribed supportive care medications for lymphoma and breast malignancies. For instance, in the UK, G-CSF is given to 84% of patients with lymphoma and 70% of breast cancer patients, respectively. However, the declining usage of myelosuppressive chemotherapy, which limits the formation of G-CSF, is a consequence of the increased use of immuno-oncology (IO) drugs in therapy, such as anti-PD-1/L1s. During the anticipated term, positive growth in the antiemetics segment is anticipated.

Chemotherapy-induced nausea and vomiting (CINV) is one of the most frequent issues that patients with chemotherapy deal with. The introduction of more recent medications including Cinvanti, Sustol, and Varubi is to blame for the rise. However, the overall CINV medicines sales would be impacted by the patent expiry of important antiemetic medications like Emend. During the projection period, the growth of the opioid segment is anticipated to slow. Opioid medicines are subject to strict controls imposed by governments in many nations, including the US government. As a result, the rate of opioid medication prescriptions has dramatically decreased.

By Application Type

The cancer supportive care drugs market has been divided into breast cancer, lung cancer, colorectal cancer, prostate cancer, liver cancer, stomach cancer, and others.

By Distribution Channel Type

The market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

Regional Analysis

The cancer supportive care drugs market is broken down geographically into areas like North America, Europe, Asia-Pacific, and the Rest of the World (RoW). The launch and quick adoption of biosimilars as well as curbs on the prescription of opioids are likely to cause the market in North America and other developed regions to contract over the course of the forecast period.

Additionally, tailored, targeted medicines are widely used in these regions due to their lower incidence of adverse effects, increasing public knowledge of their availability, and supportive reimbursement practices for expensive targeted therapies. High unmet needs for cancer supportive care exist in developing nations such as those in the Middle East and Africa, Latin America, and Asia-Pacific. Chemotherapy is still a common treatment because of the underdeveloped healthcare systems and low levels of disposable income in these areas. These elements are anticipated to fuel market expansion in these regions.

Key Players

Rising technological and therapeutic developments as well as an increase in product launches by market participants are factors driving the growth of the global market for asthma and COPD medications. For the introduction of new products, certain governmental organisations work with industry participants.

For example:

• Intas Pharmaceuticals introduced Oral Azacitidine for Acute Myeloid Leukemia in India in September 2021 under the trade name Azadine-O. It is authorised for use in adult patients with acute myeloid leukaemia who are on maintenance therapy.
• As part of the Cancer Access Partnership, Biocon Biologics Ltd. and the Clinton Health Access Initiative (CHAI) inked a contract in February 2021 to increase access to potentially life-saving cancer biosimilars including over 30 countries across Africa and Asia (CAP). The collaboration is an important step in providing cutting-edge cancer treatments to patients who need them most and ensuring fair access to high-quality biosimilars in developing and middle-income nations (LMICs). The company will make Trastuzumab & Pegfilgrastim available in Africa & Asia through this partnership.
• Pfizer's NYVEPRIA, a biosimilar to Amgen's NEULASTA, was approved in June 2020.
• The U.S. FDA granted Trodelvy (sacituzumab govitecan-hziy) expedited approval in April 2020 to Gilead Sciences, Inc.

The overall competitive landscape has been affected due to several advacnements. The following are the major players in the cancer supportive care drugs market:

• Amgen, Inc.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc (GSK)
• Helsinn Healthcare SA
• Heron Therapeutics, Inc.
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Novartis AG

Research Methodology

This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools. 

More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data. 

We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.

Report Features

This report provides market intelligence most comprehensively. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.

What Deliverables Will You Get in this Report?

Customization Options

With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

Company Profiling

• Detailed profiling of additional market players (up to three players)
• SWOT analysis of key players (up to three players)

Competitive Benchmarking

• Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances

Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com